2025-02-25 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Performance Review

This report analyzes the performance of Colgate-Palmolive Co (CL), a leading manufacturer of consumer products including oral hygiene, personal care, and pet nutrition products.

**1) Performance Comparison with S&P 500 (VOO):**

CL's cumulative return is 38.20%, significantly underperforming the S&P 500's cumulative return of 117.28%.  The difference is -79.1%, placing it at the 11.1 percentile of its historical range of performance relative to the S&P 500 (based on a minimum difference of -90.0% and a maximum of 8.2%).  This indicates consistent underperformance compared to the broader market.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 13.0% | 4.6% | -15.0% | 0.1 | 51.5 |
| 2016-2018  | -12.0% | 8.5% | -30.0% | 0.3 | 41.6 |
| 2017-2019  | 9.0% | 8.5% | -21.0% | 0.2 | 49.4 |
| 2018-2020  | 21.0% | 8.5% | -6.0% | 0.7 | 62.8 |
| 2019-2021  | 32.0% | 7.3% | -39.0% | 1.0 | 64.1 |
| 2020-2022  | 7.0% | 9.3% | -2.0% | 1.0 | 60.6 |
| 2021-2023  | 3.0% | 9.3% | -20.0% | 1.0 | 62.9 |
| 2022-2024  | 13.0% | 9.3% | -20.0% | 1.0 | 73.4 |
| 2023-2025  | 23.0% | 8.8% | -35.0% | 0.5 | 73.1 |


The analysis shows inconsistent performance with negative alpha values in most periods, suggesting underperformance relative to the market benchmark.  Beta values generally hover around 1, indicating similar volatility to the market.  However, the significant negative alpha values are a major concern.


**2) Recent Price Movement:**

* **Closing Price:** $90.11
* **5-Day Moving Average:** $88.25
* **20-Day Moving Average:** $87.80
* **60-Day Moving Average:** $90.00

The price is slightly above the 60-day moving average, suggesting a recent price recovery. However, it is still above the shorter-term moving averages, which could indicate some upward momentum.  The recent price change shows a slight increase (+0.715). This isn't a significant jump to indicate a sharp rebound.


**3) Technical Indicators:**

* **RSI (62.5):**  Suggests the stock is neither overbought nor oversold, indicating a neutral trend.
* **PPO (0.5062):** A positive value suggests bullish momentum.
* **Relative Strength Change (11.1% positive):** Indicates recent short-term upward momentum.
* **Expected Return (-368.7%):** This extremely negative expected return relative to the S&P 500 is a major red flag, implying significant underperformance is projected over the long term (2+ years).  This needs further investigation to understand the basis of this prediction.

**4) Recent Earnings Analysis:**

| Date       | EPS | Revenue      |
|------------|-----|--------------|
| 2024-10-25 | 0.9 | $5.03B       |
| 2024-07-26 | 0.89 | $5.06B       |
| 2024-04-26 | 0.83 | $5.07B       |
| 2023-10-27 | 0.86 | $4.92B       |
| 2024-10-25 | 0.86 | $4.92B       | *(Duplicate Entry, Likely an Error)*


Revenue is relatively stable around $5B, but EPS shows some minor fluctuation.  The duplicated entry needs clarification.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.95B | 60.30% |
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |

Revenue is consistent, with slight variations. Profit margins are consistently high, suggesting strong profitability.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $0.21B | 348.58% |
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |

Equity fluctuates significantly, while ROE shows extremely high and volatile values.  These extreme ROE values warrant further investigation as they seem unusually high and may indicate accounting issues or data errors.

**6) Overall Analysis:**

Colgate-Palmolive shows consistent profitability with high profit margins. However, the stock significantly underperforms the S&P 500, with negative alpha values indicating consistent underperformance relative to the market. The extremely negative projected long-term return (-368.7%) and volatile ROE figures raise serious concerns.  The data inconsistencies (duplicate earnings entry, extremely high ROE) require further investigation before drawing definitive conclusions.  Further analysis is needed to understand the reasons for the underperformance and the validity of the extremely negative long-term return prediction.  It is crucial to review the source of the data and potentially seek professional financial advice before making any investment decisions.
